Neuroactive Steroid Formulation with Cyclodextrins for CNS Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for premenstrual syndrome (PMS), postpartum depression, and essential tremor are inadequate, as existing therapies do not effectively address the underlying neurochemical imbalances associated with these conditions, particularly the fluctuations in progesterone levels and cerebellar dysfunction.
Innovation Solution
Administration of neuroactive steroids such as pregnanolone, allopregnanolone, ganaxolone, or brexanolone, either alone or in combination with cyclodextrins like β-cyclodextrin, for parenteral or oral delivery, to target CNS-related disorders including tremor, depression, and anxiety disorders, with a focus on rapid and sustained therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If neuroactive steroids are administered to treat CNS disorders, then therapeutic efficacy is improved, but risk of severe adverse events increases
Solution Approach 1:
The patent uses cyclodextrins as solubilizing agents and formulation excipients to improve the delivery and bioavailability of neuroactive steroids. This intermediary substance enables better therapeutic efficacy while controlling potential adverse effects through optimized formulation, allowing the active compound to be delivered more effectively to target sites in the CNS.
Solution Approach 2:
The patent employs phase transfer catalysts and adjusts formulation parameters (pH, ionic strength, temperature) to optimize the solubility and stability of neuroactive steroids. By changing physical-chemical parameters of the formulation system, the patent achieves improved therapeutic delivery while minimizing adverse events through controlled release and reduced toxicity.
2Speed
If neuroactive steroids are formulated for parenteral delivery, then rapid onset of action is achieved, but manufacturing complexity increases
Solution Approach 1:
The patent creates composite formulations combining neuroactive steroids with cyclodextrins and phase transfer catalysts in sterile parenteral solutions. This composite approach enables rapid onset of action through direct intravenous or intramuscular delivery while the standardized formulation components and established manufacturing processes for sterile injections help manage the complexity of production.
3Adaptability or versatility
If neuroactive steroids are used to treat multiple CNS disorders, then versatility of treatment is improved, but dosing optimization becomes more difficult
Solution Approach 1:
The patent develops a universal formulation platform using cyclodextrins and phase transfer catalysts that can deliver different neuroactive steroids (allopregnanolone, ganaxolone, brexanolone) for multiple CNS disorders including depression, anxiety, and tremor. This multi-functional approach allows a single formulation strategy to serve multiple therapeutic indications, simplifying the overall dosing optimization process across different conditions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides rapid relief from symptoms of depression, anxiety, and tremor, with sustained efficacy for several months without severe adverse events, offering an effective treatment option for conditions resistant to traditional therapies.
Implementation Method 1
compositions comprising a neuroactive steroid, e.g., pregnanolone, allopregnanolone, alphadalone, ganaxolone, or alphaxolone; and optionally a cyclodextrin, e.g., a β-cyclodextrin, e.g., a sulfo butyl ether β-cyclodextrin
Data Source
AI summary
Described herein are methods of treating a disorder, e.g., tremor, e.g., essential tremor; depression, e.g., postpostum depression; and anxiety disorder, the method comprising administering to a human subject suffering from a disorder, e.g., tremor, e.g., essential tremor; depression, e.g., postpostum depression, an anxiety disorder with a neuroactive steroid or a composition comprising a neuroactive steroid (e.g., pregnanolone, allopregnanolone, alphadalone, ganaxolone, or alphaxolone).